Meta-analysis of 29 RCTs (13 387 methotrexate-naïve adults with early RA): first-line b/tsDMARDs plus methotrexate raised DAS28 remission at 6 months vs methotrexate alone (RR 1.62). As monotherapy, only tocilizumab and JAK inhibitors showed significant class-level gains.
Meta-analysisn = 13,387
Russell et al. First-line biologic and targeted synthetic DMARDs versus methotrexate in early rheumatoid arthritis: a meta-analysis of remission outcomes